Expression of NF-κB and IL-6 in oral precancerous and cancerous lesions: an immunohistochemical study by Kamperos, Georgios et al.
Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 (1):e6-13.                                                                                                                                                    NF-κΒ and IL-6 in oral precancer and cancer
e6
Journal section: Oral Medicine and Pathology
Publication Types: Research
Expression of NF-κB and IL-6 in oral precancerous and cancerous 
lesions: An immunohistochemical study
Georgios Kamperos 1, Nikolaos Nikitakis 2, Aikaterini Sfakianou 1, Dimitrios Avgoustidis 3, Alexandra 
Sklavounou-Andrikopoulou 4
1 DDS, MSc. Postgraduate student, Department of Oral Medicine and Pathology, School of Dentistry, University of Athens, 
Greece
2 MD, DDS, PhD. Associate Professor, Department of Oral Medicine and Pathology, School of Dentistry, University of Athens, 
Greece
3 MD, DDS. Resident, Department of Oral and Maxillofacial Surgery, “Evaggelismos” Hospital, University of Athens, Greece
4 DDS, MSc, DrDent. Professor and Head, Department of Oral Medicine and Pathology, School of Dentistry, University of 
Athens, Greece
Correspondence:
2-4, Alkmaionidon St
16121, Athens, Greece
gkamperos@yahoo.gr
Received: 27/12/2014
Accepted: 07/10/2015
Abstract
Background: The purpose of this study was to evaluate the immunohistochemical expression of NF-κB and 
IL-6 in oral premalignant and malignant lesions and to investigate their possible correlation with the presence of 
subepithelial inflammation. 
Material and Methods: Thirty two oral premalignant lesions, clinically compatible with leukoplakia or 
erythroplakia, were investigated. Microscopically, 11 of them showed hyperkeratosis and acanthosis (epithelial 
hyperplasia) and 21 showed dysplasia of varying degrees. Nine cases of OSCC and four control cases of normal 
oral mucosa were also included in the study. Immunohistochemical staining with NF-κB (p65) and IL-6 was 
performed. IL-6 and nuclear NF-κB staining were assessed as positive or negative. For cytoplasmic localization 
of NF-κB, a total score combining intensity and percentage of positive epithelial cells was additionally calculated. 
The presence of inflammation was also recorded.
Results: Intensity and total scores for NF-κΒ cytoplasmic immunostaining showed a statistically significant 
gradual increase from normal mucosa to OSCC (p=0.012 and p=0.026 respectively). Non-statistically significant 
increased NF-κΒ nuclear localization was detected in dysplasias and OSCCs. Positive statistical correlation was 
detected between the presence of inflammation and IL-6 expression (p=0.015). No correlation between NF-κΒ 
and IL-6 was detected.
Conclusions: NF-κΒ is activated in the early stages of oral carcinogenesis. IL-6 may have an NF-κΒ-independent 
role, possibly through regulation of the inflammatory response.
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Introduction
The study of potentially malignant disorders offers 
insight into the pathogenesis of oral cancer. Furthermore, 
continuing investigation of the molecular basis of oral 
carcinogenesis may help to distinguish lesions with 
increased malignant potential and to discover new 
targets for molecular chemotherapy. It is widely known 
that carcinogenesis may occur through evolution of 
precancerous lesions or conditions (1). A precancerous 
lesion is a morphologically altered tissue in which oral 
cancer is more likely to occur than in its apparently normal 
counterpart (2). The most common precancerous lesions 
in oral mucosa are leukoplakias and erythroplakias (1).
The role of inflammation is implicated in the pathogenesis 
of cancer. It is estimated that 15-20% of all cancers are 
etiologically associated with inflammation, especially 
of chronic type (3). Tumor cells are known to produce 
inflammatory agents in order to alter the stroma and 
facilitate invasion (4). Increased inflammatory cytokine 
levels are found in many cancer cell lines including 
oral squamous cell carcinoma (OSCC) (5). Laboratory 
trials showed that even acute inflammation may lead to 
increased invasion and metastases (3). Inflammation is 
also related to the expression of several oncogenes, such 
as RAS and MYC (6).
The transcription factor Nuclear Factor-kappa B (NF-
κB) has been extensively studied in carcinogenesis (7). 
Mammalian NF-κB protein family is composed of five 
members, RelA (p65), RelB, cRel (Rel), NF-κB1 (p50 
and its precursor p105) and NF-κB2 (p52 and its precur-
sor p100) (8). These molecules form homodimeric and 
heterodimeric complexes, the activity of which is regu-
lated by different pathways (8). The classical pathway of 
NF-κB is the most commonly studied due to its major 
role in the control of innate immunity and inflamma-
tion (8). It is modulated by the p65:p50 dimer, which is 
constantly inactive in the cytoplasm bound to inhibitory 
molecules (Inhibitors of κΒ–ΙκΒs) (8). Various condi-
tions initiate the degradation of the IκΒs, so that the 
ΝF-κΒ complex is freed to enter the nucleus and acti-
vate target genes (8).  Specifically, NF-κΒ regulates the 
expression of proteins that have prominent roles in cell 
proliferation, survival, immune response and inflam-
mation, such as Interleukin-6 (IL-6) (7,9).
IL-6 is a pro-inflammatory cytokine with autocrine 
and paracrine functions (10). It binds to a membrane 
receptor, which is a heterodimer-composed of IL-6 
special receptor protein (IL-6Ra/gp80 or CD126) and 
gp130 (CD130) (10). IL-6 receptor (IL-6R) activates 
the Janus kinase family (JAK1, JAK2, TYK2) via 
gp130 (10). In turn, these kinases activate the molecular 
pathways of Signal transducer and activator of 
transcription 3 (STAT3), Phosphoinositide 3-kinase 
(PI3K) and Mitogen-activated protein kinases (MAPKs) 
with various oncogenic consequences (4,10). 
Currently, no studies have explored the immunohisto-
chemical correlation between NF-κB and IL-6 in oral 
precancerous lesions. The aim of this study was to eva-
luate the immunohistochemical expression of NF-κB 
and IL-6 in oral precancerous lesions (leukoplakias and 
erythroleukoplakias) and to investigate their possible 
correlation with the presence of subepithelial inflam-
matory infiltrate. 
Material and Methods
* Material
Forty five biopsies were retrieved from the files of the 
Department of Oral Medicine and Pathology, Dental 
School, National and Kapodistrian University of 
Athens. Thirty two oral premalignant lesions, clinically 
compatible with leukoplakia or erythroplakia, were 
investigated. Microscopically, 11 of them showed 
hyperkeratosis and acanthosis (epithelial hyperplasia) 
and 21 showed dysplasia of varying degrees. Nine cases 
of OSCC and four control cases of normal oral mucosa 
were also included in the study. The histological 
features were reviewed for confirmation of the diagnosis 
according to the WΗΟ 2005 guidelines. The research 
protocol was IRB approved.
The available epidemiological and clinical characteristics 
were collected. All precancerous lesions presented 
clinically as leukoplakia or erythroleukoplakia without 
a history of previous interventions. The normal mucosa 
cases were harvested from sites adjacent to reactive oral 
mucosal lesions in patients with no medical history of 
oral premalignancy or malignancy and no social history 
of smoking or excessive alcohol drinking.
* Methods
- Immunohistochemistry 
Paraffin-embedded tissue sections of 5μm thickness 
were deparaffinized (5 min in 60oC), immersed in 
xylene and ethanol solutions, and heated for antigen 
retrieval in 0.01 M citrate buffer for 15 min in a pressure 
cooker inside a microwave oven. After incubation in 
3% hydrogen peroxide (LSAB+ kit Dako Corporation, 
Carpinteria USA) to neutralize endogenous peroxidase 
activity and treatment with Protein Free Serum 
(LSAB+ kit Dako Corporation, Carpinteria USA) to 
reduce nonspecific binding of primary antibody and 
polymer, the sections were incubated with primary 
antibodies overnight. The applied antibodies were 
monoclonal anti-p65 mouse antibody (sc-8008, Santa 
Cruz Biotechnology, Santa Cruz, California, USA) 
diluted at 1:200 and monoclonal anti-IL-6 mouse 
antibody (clone 6708.11, Sigma, Saint Louis, Missouri, 
USA) diluted at 1:25. Standard streptavidin–biotin–
peroxidase complex method was employed to bind to 
the primary antibody along with multilink concentrated 
biotinylated anti-IgG as secondary antibody (LSAB+ kit 
Dako). Reaction products were visualized by staining 
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with 3,3V-diaminobenzidine reagent (LSAB+ kit 
Dako). Sections were counterstained with hematoxylin. 
As positive controls, the following were used: OSCC 
for p65 and papillary thyroid carcinoma for IL-6 with 
corresponding known positivity. As a negative control, 
sections were treated with PBS, with the omission of the 
primary antibody. 
- Immunohistochemical scoring 
Immunostains were reviewed by three independent 
evaluators (N.N., G.K. and A.S.). Immunohistochemical 
reactivity for NF-κB (p65) was assessed separately 
in the cytoplasm and in the nucleus of the epithelial 
cells since it has been suggested that this molecule’s 
localization may represent a transition between inactive 
and active forms (8). NF-κB cytoplasmic staining 
was graded according to the percentage of positive 
epithelial cells (0, 0%; 1, < 20%; 2, 20–50%; 3, > 50%) 
(Fig 1A-C) and intensity of staining (0, no staining; 1, 
weak; 2, moderate; 3, strong) (Fig 1D-F) compared to 
Fig. 1. Cytoplasmic NF-κΒ (p65) staining grades according to the percentage of positive epithelial cells [1, < 20% (A); 2, 20–50% (B); 3, > 50% 
(C)] and the intensity of staining [1, weak (D); 2, moderate (E); 3, strong (F)]. Note the prominent positive nuclear staining in C. (A-F: 100X).
negative control tissues; a combined score (0-6) was 
also calculated. NF-κB nuclear staining in the epithelial 
cells was characterized as positive or negative (due to 
primarily focal localization, no further assessment 
was performed). Immunohistochemical cytoplasmic 
reactivity for IL-6 was characterized as positive or 
negative.
- Assessment of inflammation
Inflammation was microscopically assessed on hema-
toxylin and eosin stains. If subepithelial inflammatory 
infiltrate (mild to severe) was noted, the case was char-
acterized as positive. The absence of subepithelial in-
flammation resulted in the characterization of the spe-
cific case as negative. 
- Statistical analysis
The baseline characteristics of patients were summarized 
as mean and standard deviation (SD) for continuous 
or ordinal data and as absolute (n) and relative (%) 
frequency for categorical variables. The two tailed 
Fisher’s exact test was performed in order to evaluate 
possible differences in the frequency distribution 
of clinical and pathologic features of patients or the 
parameters of p65 immunohistochemical expression, 
according to the histological classification of lesions. 
The same test was also performed to evaluate possible 
associations between various parameters of IL-6 
immunohistochemical expression and the presence of 
inflammation. The Mantel-Hæszel method was then 
applied for the calculation of odds ratios (OR) and 
their respective 95% confidence intervals (95% CI) in 
2 x 2 contingency tables, wherever possible. Pearson 
Correlation Coefficients (r) were calculated between all 
dichotomous variables and inflammation presence, as 
well.
Comparisons concerning the age of patients were based 
on one-way ANOVA, while ordinal data were compared 
with the use of the Kruskal-Wallis one way analysis of 
variance by ranks. Post – hoc pairwise comparisons 
after a significant Kruskal-Wallis test were carried out 
with the application of Dunn’s test.
Statistical analyses were performed using the SPSS 
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software application (version 21.0: SPSS, Chicago, IL, 
U.S.A.) with p<0.05 as the threshold of significance.
Results
- Cohort characteristics
Distribution of the demographic characteristics (sex, 
age and location) according to the histologic type is pre-
sented in table 1. No statistically significant difference 
was observed in the distribution of these parameters be-
tween different histologic types.
- Presence of inflammation
Subepithelial inflammatory infiltrate (primarily of 
chronic nature) was observed in 0/4 cases of normal 
epithelium (0%), 9/11 cases of epithelial hyperplasia 
(81.8%), 17/21 cases of dysplasia (81%) and 9/9 cases 
of OSCC (100%) (p=0.002) (Table 1). Compared with 
normal mucosa, the presence of inflammation was higher 
in epithelial hyperplasias (p=0.011, 95% confidence 
interval [CI] lower border 2.95), dysplasias (p=0.006, 
95% CI lower border 3.41) and OSCCs (p=0.001, 95% 
CI lower border 9.93). 
- NF-κΒ immunohistochemical expression
NF-κB (p65) cytoplasmic expression was detected in the 
epithelial cells of all cases; as expected, p65 expression 
was also seen in the subjacent inflammatory cells. The 
average percentage, intensity and total scores for NF-
κB cytoplasmic expression in the epithelial cells are 
presented in table 2. No statistical significant difference 
was detected in the percentage score for p65 positive 
cells. On the other hand, average intensity scores showed 
a statistically significant gradual increase from normal 
mucosa to OSCC (p=0.012) (Table 2) (Fig. 2). Post-
hoc analysis revealed that the greatest difference was 
observed in the transition from epithelial hyperplasia 
to dysplasia (p=0.011). Moreover, total scores for NF-
κB cytoplasmic expression also showed a similar (to 
intensity) statistically significant difference between 
the histological categories (p=0.026) (Table 2).
 NF-κΒ nuclear localization was detected in clusters 
of cells in 0/4 (0%) of the normal mucosa cases, 2/11 
(18.2%) of the epithelial hyperplasia cases, 8/21 (38.1%) 
of the dysplasia cases and 3/9 (33.3%) of the OSCC 
cases (Table 2) (Fig. 1C). Even though there seems to 
be an increased number of cases exhibiting nuclear 
                     Histologic classification of lesion    
Characteristics Normal
Epithelial 
Hyperplasia 
Epithelial
Dysplasia OSCC P* Cohort
No of cases 4 (8.9%) 11 (24.4%) 21 (46.7%) 9 (20.0%)  45 (100.0%) 
Sex    
Men 0 (0.0%) 5 (25.0%) 10 (50.0%) 5 (25.0%) 0.325 
 20 (44.4%) 
Women 4 (16.0%) 6 (24.0%) 11 (44.0%) 4 (16.0%)  25 (55.6%) 
Age (years)    
Mean ± SD 51.0 ± 9.3 48.2 ± 9.1 55.6 ± 12.8 62.2 ± 10.9 0.059**  54.7 ± 12.0 
Range 38 – 60 29 – 57 30 – 69 50 – 82  29 – 82 
55 3 (14.3%) 8 (61.5%) 7 (53.8%) 3 (23.1%) 0.097 
 21 (46.7%) 
>55 1 (4.2%) 3 (14.3%) 14 (66.7%) 6 (28.6%)  24 (53.3%) 
Location    
Buccal mucosa 4 (30.8%)   3 (23.1%)   4 (30.8%) 2 (15.4%)   
 
reference 
  
13 
 
(28.9%) 
 
Tongue &  
floor of mouth 0 (0.0%)   2 (11.8%)   11 (64,7%) 4 (23.5%)   
 
 
0.056 
  
 
17 
 
 
(37.8%) 
 
Maxillary / 
mandibular 
mucosa 
0 (0.0%)   3 (25.0%)   6 (50.0%)  3 (25.0%)   0.221 
 
12 (26.7%) 
 
Palate 0 (0.0%)   3 (100%)   0 (0.0%) 0 (0.0%)   
 
0.118 
  
3 
 
(6.7%) 
Inflammation    
Yes 0 (0.0%) 9 (25.7%) 17 (48.6%) 9 (25.7%) 0.002 
 35 (77.8%) 
No 4 (40%) 2 (20.0%) 4 (40.0%) 0 (0.0%)  10 (22.2%) 
Table 1. Patients’ clinical characteristics and presence of inflammation per histologic type of lesions.
Abbreviation: SD, Standard deviation.
*Two-tailed Fisher’s exact test.
**One way analysis of variance.
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Histologic classification of lesion 
p65 IHC expression parameters Normal
(n=4) 
Epithelial
Hyperplasia 
(n=11) 
Epithelial
Dysplasia 
(n=21) 
OSCC
(n=9) P*
Cellular sites of p65 
Cytoplasm only 4 (12.5%) 9 (28.1%) 13 (40.6%) 6 (18.8%) 
0.448 Nucleus only 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Cytoplasm & Nucleus 0 (0.0%) 2 (15.4%) 8 (61.5%) 3 (23.1%) 
Absent 0 (0.0%) 0 0.0% 0 (0.0%) 0 (0.0%) 
Percentage of cells score of 
cytoplasmic p65 
Mean Score 2.8 2.7 2.9 2.8 0.752** 
Range 2 – 3 1 – 3 2 – 3 2 – 3 
Score 2 1 (14.3%) 2 (28.6%) 2 (28.6%) 2 (28.6%) 0.580 
Score 3 3 (7.9%) 9 (23.7%) 19 (50%) 7 (18.4%) 
Intensity score of  
cytoplasmic p65  
Mean Score 1.5 1.7 2.4 2.4 0.012** 
Range 1 – 2 1 – 3 1 – 3 1 – 3 
Score 2 4 (14.3%) 10 (35.7%) 10 (35.7%) 4 (14.3%) 0.022 
Score 3 0 (0%) 1 (5.9%) 11 (64.7%) 5 (29.4%) 
Total score of  
cytoplasmic p65 
Mean Score 4.3 4.5 5.3 5.2 0.026** 
Range 3 – 5 2 – 6 3 – 6 4 – 6 
Score <=3 1 (20%) 2 (40%) 2 (40%) 0 (0%) 0.387 
Score >3 3 (7.5%) 9 (22.5%) 19 (47.5%) 9 (22.5%) 
Table 2. Comparison of p65 immunohistochemical parameters between different histologic types of lesions.
Abbreviations: IHC, Immunohistochemistry.
*Two-tailed Fisher’s exact test.
**The Kruskal–Wallis one way analysis of variance by ranks.
Fig. 2. NF-κΒ (p65) immunohistochemical staining in normal tissue (A), epithelial hyperplasia (B), 
epithelial dysplasia (C) and OSCC (D), showing a gradual increase in cytoplasmic intensity from 
normal to cancer. (A-D: 100X).
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localization among dysplasias and OSCCs, no statistical 
significant difference was observed.
There was no statistical correlation between the 
expression of NF-κΒ (p65) and the presence of the 
subepithelial inflammatory infiltrate (data not shown).
- IL-6 immunohistochemical expression 
IL-6 had a generally mild cytoplasmic staining in a few 
subepithelial inflammatory cells and in the adjacent 
epithelial cells of the basal or parabasal layer of selective 
cases (Fig. 3). 
Specifically, IL-6 expression was detected in 3/11 
(27.3%) of the epithelial hyperplasia cases, 10/18 (55.6%) 
of the dysplasia cases and 2/7 (28.6%) of the OSCC 
cases, whereas no positive case was detected in normal 
oral mucosa. No statistical difference was observed 
between the above groups. Overall, epithelial dysplasias 
showed non-statistically significant increased positivity 
for IL-6 compared to hyperplasias and OSCCs. 
There was no statistical correlation between the expres-
sion of IL-6 and the nuclear or cytoplasmic expression 
of NF-κΒ (p65). On the other hand, positive statistical 
correlation between the presence of inflammation and 
the expression of IL-6 was detected (p=0.015, 95% con-
fidence interval [CI] lower border 1.99) (Table 3). 
Discussion
The role of chronic inflammation in oral carcinogenesis 
is not fully understood. Transcription factor NF-κΒ 
is known to have prominent role in the inflammatory 
response (3,9). Moreover, proinflammatory cytokines, 
such as IL-6, are often involved in the interaction 
between epithelial and stromal cells (6,9). The current 
study’s objective was to evaluate the expression of 
these key molecules in oral precancerous and cancerous 
lesions and correlate it with each other, with the 
histologic subtype of the lesions and with the presence 
of subepithelial inflammatory infiltrate.
NF-κΒ pathway is implicated in oral carcinogenesis. 
Among its family members, p65 is the most frequently 
studied. It is part of the p65(RelA):p50 dimer which 
mediates the classical pathway. In the present study, 
p65 was expressed in the cytoplasm of the epithelial 
Fig. 3. IL-6 immunohistochemical staining in subepithelial inflammatory cells (black arrows) and in the adjacent epithelial cells of the basal or 
parabasal layer (white arrows) of selective cases. (A-B: 400X).
Presence of inflammation 
Parameters of IL-6 IHC expression + - P* OR (95% CI) 
No of cases 35 (77.8%) 10 (22.2%) 
Not available for IL-6 analysis 4 (80.0%) 1 (20.0%) 
IL-6 expression 
Expressed 15 (100.0%) 0 (0.0%) 0.015 N.C. (1.99 – N.C.) 
Not expressed  16 (64.0%) 9 (36.0%) Reference 
Table 3. Correlation of IL-6 immunohistochemical expression with inflammation.
Abbreviations: N.C., Non calculable. IHC, Immunohistochemistry. OR, odds ratio. CI, confidence intervals
*Two-tailed Fisher’s exact test.
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cells in every case. This finding may be attributed to 
the sensitivity of the anti-p65 antibody used. The same 
antibody was used in other studies also, revealing high 
p65 expression rates (7,11). It should be noted that the 
cytoplasmic expression of p65 in OSCC is over 75% 
in various studies, while nuclear staining is detected 
in just 35-45% of the cases (7,11-16). In the present 
study, nuclear localization was detected in 33.3% of 
OSCC cases. As for the oral precancerous lesions, it 
is generally believed that p65 expression (percentage 
and intensity) gradually increases from normal mucosa 
to epithelial dysplasia (13-16). In the present study, 
p65 cytoplasmic intensity and total scores showed a 
statistically significant gradual increase from normal 
mucosa to OSCC, while non-statistically significant 
increased nuclear localization was detected in epithelial 
dysplasias and OSCCs. These findings suggest that p65 
may be expressed in all stages of oral carcinogenesis 
with increased expression especially in the transition 
between oral epithelial hyperplasia and dysplasia. 
Chronic inflammation and IL-6 in particular, are involved 
in colon and prostate carcinogenesis (17-19). In the 
present study, the non-statistically significant increased 
IL-6 expression in epithelial dysplasias compared to 
hyperplasias and normal mucosa suggests a possible 
role of this molecular pathway in oral carcinogenesis. 
Interestingly, no other studies have tested IL-6 
immunohistochemical expression in oral precancerous 
lesions. As for OSCC, only 2/7 cases (28.6%) were positive 
for IL-6. Other immunohistochemical studies have found 
that 35.7-100% of OSCC tissues or cell lines express IL-6 
(20-24). This disagreement can be attributed to the small 
sample (n=7) of the research. On the other hand, these 
tumors may still express IL-6R in order to receive IL-6 
signaling from the subepithelial inflammatory infiltrate, 
as suggested by other studies (24). 
In the present study, increased presence of inflammation 
was detected in epithelial hyperplasias, dysplasias 
and OSCCs, compared with normal mucosa. In 
addition, a statistically significant correlation between 
IL-6 expression and the presence of subepithelial 
inflammatory infiltrate was observed. These findings 
should be interpreted in the context of a possible 
crosstalk between the epithelium and the stroma in oral 
carcinogenesis. The inflammatory cells (macrophages 
and lymphocytes) typically produce IL-6 that binds 
to the epithelial cells via IL-6R and/or sIL-6R, thus 
facilitating cellular growth and invasion (4,9,25,26). 
Moreover, inflammatory cells also express IL-6R and 
are able to receive signals from the epithelium (27,28). 
These molecular signals cause oncogenic differentiation 
of the inflammatory infiltrate towards Th2 lymphocytes 
and M2 macrophages (29). The exact role of IL-6 in 
the early stages of oral carcinogenesis, before invasive 
carcinoma is formed, needs further investigation. 
The expression of IL-6 is commonly regulated by NF-
κB (7). In the present study, no correlation between the 
expression of IL-6 and the nuclear or cytoplasmic ex-
pression of NF-κΒ (p65) was noted. This fact indicates 
that NF-κΒ may act in an IL-6-independent fashion by 
activating different targets in oral carcinogenesis, such 
as the anti-apoptotic protein Bcl-2 and various other 
cytokines and chemokines (30). Moreover, IL-6 might 
be activated by molecules other than NF-κΒ, such as 
Interleukin-1 (IL-1), Tumor necrosis factor (TNF), pros-
taglandin E-2 (PGE-2) and vascular endothelial growth 
factor (VEGF) (9).
The results of this study support that the signaling path-
way of NF-κΒ is activated in the early stages of oral car-
cinogenesis. At the same time, IL-6 might have an in-
dependent role in the regulation of the inflammatory re-
sponse. Interestingly, the intensity of NF-κΒ expression 
is significantly increased in the transition from epithe-
lial hyperplasias to dysplasias. The increased presence 
of inflammation in epithelial hyperplasias, dysplasias 
and OSCCs and its statistical correlation with IL-6 ex-
pression is consistent with a possible crosstalk between 
the epithelium and the stroma. On the other hand, the 
absence of correlation between NF-κB expression and 
IL-6 expression suggests that this cytokine may be the 
downstream target of other NF-κB-unrelated molecu-
lar pathways. Further studies regarding these processes 
may be of significance in the quest for better prognosti-
cation and/or management of potentially malignant dis-
orders of the head and neck.
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